In vitro studies have indicated that reactive oxygen species modifying cellular redox status are involved in hypoxia-induced erythropoietin (EPO) production. However, the effects of redox balance on hypoxia-induced EPO production in vivo are still not fully understood. To investigate the effect of the change in cellular redox status on EPO generation, we determined whether glutathione (GSH) depletion has a significant influence on hypoxia-induced EPO production in rats. For the inhibition of GSH synthesis, DLbuthionine-[S,R]-sulfoximine (BSO) was employed by intraperitoneal injection. Twenty male rats were assigned to one of four experimental groups: (1) normoxic placebo, (2) normoxic BSO, (3) hypoxic placebo, and (4) hypoxic BSO. Hypoxic groups were exposed to a simulated normobaric hypoxic condition (4,500 m above sea level) for 12 hours. BSO treatment resulted in a significant depletion of total GSH levels in kidney and plasma in both conditions. However, the hypoxia-induced elevation in serum EPO concentration was not completely affected by the inhibition of GSH synthesis. These data demonstrate that GSH depletion in the kidney is not involved in the increase in serum EPO concentration in response to systemic hypoxia. It is also conceivable that the cellular redox changes could not function as a primary regulator of hypoxia-induced renal erythropoietin formation in vivo.
Introduction
Glycoprotein hormone erythropoietin (EPO) is produced in the kidney and fetal liver in response to hypoxia. The hypoxic response of EPO is controlled by an enhancer element located in the 3Ј-flanking region of the EPO gene (Semenza and Wang, 1992) . Transcriptional activation of the enhancer is facilitated by the binding of hypoxia-inducible factor-1 (HIF-1) to a hypoxia response element. HIF-1 is a heterodimeric transcription factor composed of a and b subunits (Wang et al., 1995a) . HIF-1a and HIF-1b mRNA are constantly expressed under normoxic and hypoxic conditions, suggesting that HIF-1 is mainly regulated by a post-translational mechanism (Huang et al., 1996) . Although HIF-1b protein is constitutively expressed, HIF-1a protein is maintained at extreme low amounts under normoxic condition because of its rapid degradation by the ubiquitin-proteasome pathway (Kallio et al., 1999; Salceda and Caro, 1997; Sutter et al., 2000) . Theoretically, hypoxia inhibits degradation of HIF-1a, and then results in an accumulation of HIF-1a leading to enhanced EPO production. Recent findings have indicated many factors that may be involved in stabilization of HIF-1a, including prolyl hydroxylases, mitogen-activated protein kinase, nitric oxide, and so on (Bruick and McKnight, 2002; Huang et al., 1999; Ivan et al., 2001; Jaakkola et al., 2001; Richard et al., 1999; Sogawa et al., 1998) . Hence, HIF-1 activity to promote EPO generation is considered to be regulated by multiple posttranslational modulation of HIF-1a.
In vitro studies have suggested that reactive oxygen species (ROS) are closely related to the HIF-1 regulation pathway (Huang et al., 1996; Kietzmann et al., 2000; Wang et al., 1995b) . Fandrey et al. (1997) detected that hydrogen peroxide (H 2 O 2 ) decreases EPO mRNA and EPO protein levels in hepatoma cell lines. Furthermore, in vitro research has demonstrated that antioxidant substances enhance hypoxiainduced EPO production (Fandrey et al., 1994; Neumcke et al., 1999) . These reports strongly indicate that EPO generation via the HIF-1 pathway is partly dependent on intercellular redox balance.
However, there are few studies investigating whether redox status has a vital role in hypoxia-induced EPO production in vivo. Two human studies have indicated that various antioxidant supplementations have an insignificant effect on EPO secretion in response to systemic normobaric hypoxia (Freudenthaler et al., 2002; Niess et al., 2004) . On the other hand, oral administration of N-acetyl-cysteine (NAC), a precursor of glutathione (GSH), has been suggested to enhance hypoxia-induced EPO production (Hildebrandt et al., 2002) . Thus, the effect of redox balance on hypoxia-inducible erythropoiesis in vivo remains controversial. In addition, the influence of prooxidative treatment on the EPO response to hypoxia has not been investigated yet in vivo. We then focused on GSH, a thiol-containing antioxidant found in virtually all animal cells at high concentration. The most important antioxidative function of GSH is to serve as a substrate for glutathione peroxidase to remove ROS, especially H 2 O 2 and organic peroxide. To evaluate the hypothesis that hypoxiainduced EPO secretion is controlled by cellular redox changes, we employed DL-buthionine-[S,R]-sulfoximine (BSO), a specific inhibitor of glutathione synthesis. Hence, the primary purpose of this study was to investigate the effect of glutathione depletion on serum EPO concentrations after acute exposure to systemic normobaric hypoxia in rats.
Effects of Glutathione Depletion on Hypoxia-induced Erythropoietin

Production in Rats
Methods
Animals and experimental design
Twenty male Wistar rats (8 weeks old, body mass 290-320 g) were obtained from Clea Japan, Inc. (Shizuoka, Japan). During the experimental protocol, they were housed in an animal room maintained at 20°C and illuminated on a 12:12 light-dark cycle, and provided with food (MF, Oriental Yeast, Tokyo, Japan) and water ad libitum.
Rats were randomly assigned to one of four experimental groups: (1) normoxia, placebo (NP), (2) normoxia, BSOtreated (NB), (3) hypoxia, placebo (HP), and (4) hypoxia, BSO-treated (HB). BSO-treated groups (i.e., NB and HB) were intraperitoneally injected with BSO at a dose of 4 mmol · kg body mass Ϫ1 dissolved in 3-ml phosphate buffered saline (PBS: 136 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ), 2 h prior to exposure to hypoxic/normoxic condition. Placebo groups (i.e., NP and HP) received an equal volume of PBS injections in the same fashion as the BSO-treated groups. Two hours after i.p. injection, HP and HB groups were exposed to a simulated altitude of 4,500 m above sea level (inspired oxygen fraction FIO 2 12.0%) in a normobaric hypoxic chamber (YKS, Nara, Japan) for 12 hours. NP and NB groups were exposed to normoxia at sea level throughout the experiment. All experimental procedures were in accordance with the guidelines of the ethical committee for animal experiments of University of Yamanashi.
Sample preparation and assays
Immediately after the 12-h exposure, all the rats were exanguated from the abdominal aorta under anesthesia with ether. The kidneys were quickly excised, rinsed in ice-cold saline, snap-frozen in liquid nitrogen, and stored at Ϫ80°C until assay. Serum was prepared for assay of EPO concentration. Plasma samples were mixed with a half volume of 5% sulfosalicylic acid and centrifuged at 1,000 g for 15 min at 4°C, and the supernatant was stored at Ϫ80°C for the measurement of total GSH concentration. The kidneys were homogenized in 10 volumes of 5% sulfosalicylic acid. The homogenates were centrifuged at 1,000 g for 15 min at 4°C. The supernatant was used for determination of renal GSH contents. Plasma GSH concentrations and renal GSH contents were determined with a commercially available kit (Total Glutathione Quantification Kit, Dojin Chemistry, Kumamoto, Japan). Serum EPO concentrations were assayed by a twoantibody radioimmunoassay using 125I-labeled EPO and standard recombinant EPO samples with a commercial kit (Recombigen EPO kit, Japan DPC Co., Tokyo, Japan).
Statistical analysis
The data was analyzed by two-way ANOVA (conditionϫtreatment). The significance level was established at pϽ0.05. All results are expressed as meansϮmean standard errors.
Results
Total glutathione (GSH)
For determination of the effectiveness of BSO treatment to inhibit glutathione synthesis, GSH levels in both plasma and kidney were measured in all groups.
The plasma GSH concentrations of NP, NB, HP, and HB were 5.4Ϯ0.9, 1.6Ϯ0.4, 3.6Ϯ1.0, and 1.2Ϯ0.3 mmol/L, respectively. Between the hypoxic groups (i.e., HP and HB), a marked decrease in the plasma GSH level was also observed by the BSO treatment to the same extent in normoxic condition (Fig. 1) . Two-way ANOVA indicated a significant main effect of drug treatment on the plasma GSH values (pϽ0.01), whereas the main effect of condition was not significant (pϭ0.13). There was no significant interaction (pϭ0.34, Fig. 1) .
The renal GSH concentrations of NP, NB, HP, and HB were 2.0Ϯ0.1, 0.8Ϯ0.1, 2.1Ϯ0.1, and 0.9Ϯ0.2 mmol/g wet mass, respectively. Renal GSH content was reduced to less than 40% by the treatment of BSO in both normoxic and hypoxic groups (Fig. 2) . As indicated in Fig. 2 , two-way ANOVA revealed a significant main effect of drug treatment on the renal GSH values (pϽ0.01), whereas the main effect of condition was not significant (pϭ0.38). There was no significant interaction (pϭ0.88). The degree of the reduction in the renal GSH contents by the BSO treatment in normoxia was completely matched with that in hypoxia.
Erythropoietin (EPO)
The serum EPO concentrations of NP, NB, HP, and HB were 12.7Ϯ0.5, 12.9Ϯ1.1, 136.3Ϯ6.5, and 134.2Ϯ6.9 mU/ml, respectively. Serum EPO concentration considerably increased to approximately 10-to 11-fold greater values following an acute 12-h hypoxic exposure, in both placebo and BSO treated groups (Fig. 3) . Two-way ANOVA indicated significant main effect of condition on the serum EPO values (pϽ0.01), whereas the main effect of drug treatment was not significant (pϭ0.84). There was no significant interaction (pϭ0.81), indicating an insignificant effect of BSO treatment on hypoxiainduced EPO production (Fig. 3 ).
Discussion
Many in vitro studies using EPO-producing hepatoma cell lines demonstrate the effect of ROS on EPO-gene expression and EPO generation under hypoxic conditions (Fandrey et al., 1994; Huang et al., 1996; Imagawa et al., 1996; Neumcke et al., 1999; Wang et al., 1995b; Zhu and Bunn, 1999) . Based on these observations, it is speculated that the response of EPO to hypoxia is dependent on cellular redox changes during hypoxic stimulus. Thus, we need to examine whether ROS acts as a key modulator in hypoxia-mediated EPO production in vivo. BSO employed in this experiment has been proven to inhibit glutamyl-cysteine synthetase, a rate-limiting step enzyme of GSH synthesis, resulting in the reduction of GSH contents in various tissues such as liver, lung, and kidney (Griffith and Meister, 1979; Kramer et al., 1985; Soejima et al., 2000) . Because GSH acts to scavenge ROS as well as to regenerate other antioxidants, BSO treatment might lead the changes in cellular redox balance (Ganafa et al., 2002) . Therefore, we conducted the first in vivo study to investigate the effect of GSH depletion on EPO production by acute systemic exposure to normobaric hypoxia in rats.
Consistent with previous studies, GSH levels in both plasma and kidney were significantly decreased 14 h after a single BSO injection. These changes confirm a strong and prolonged inhibitory activity of BSO for GSH synthesis and indicate the augmentation in oxidative stress in the kidney. From a comparison between hypoxic and normoxic groups, it is clear that normobaric hypoxic exposure itself has only a slight, if any, influence on GSH levels. Whereas an enhanced production of ROS during exposure to hypoxia was observed in a previous study (Wood et al., 1999) , antioxidative status evaluated by GSH content was maintained at normoxic control level in the present study. With regard to this inconsistency, we should consider the severity of hypoxia, namely, duration, inspired oxygen fraction, etc. in future investigations.
The most important finding of the present study is that GSH depletion has no influence on the changes in serum EPO concentration induced by systemic exposure to hypoxia. To our knowledge, this is the first study to investigate the direct relationship between renal GSH level and hypoxia-mediated EPO secretion in intact animals. Recent observation has suggested the view that EPO production is modulated by the intracellular GSH level, and the effect may be associated with its scavenging property of ROS (Hildebrandt et al., 2002) . Adversely, we demonstrated a considerable hypoxia-induced elevation in serum EPO concentration, in spite of the dramatic reduction in renal GSH content by BSO treatment (less than 40%). Since GSH serves as a substrate for glutathione peroxidase to remove H 2 O 2 and organic peroxide, our findings also imply that ROS, especially H 2 O 2 and organic peroxide, might not be involved in the central regulation of hypoxiainduced EPO generation. This speculation is confirmed by recent human studies where no significant influence of antioxidant (N-acetylcysteine a-tocophenol, b-lipoic acid) administration on hypoxia-induced EPO production is detected (Freudenthaler et al., 2002; Niess et al., 2004) . From these points, we support the notion that cellular redox status may not function as a primary regulator of renal EPO formation in response to acute systemic hypoxia in rats. In our in vivo study, it was demonstrated that redox balance evaluated by GSH alteration had a minor contribution to hypoxia-induced EPO generation. However, in vitro studies, the change in redox balance is reported as a main modulator for hypoxia-induced EPO generation (Fandrey et al., 1994; Imagawa et al., 1996; Neumcke et al., 1999) . In fact, several redox-related factors, including nitric oxide, thioredoxin, and redox factor-1, have been suggested as an essential molecule for the regulation of HIF-1a in vitro (Sogawa et al., 1998; Ema et al., 1999; Carrero et al., 2000) . The discrepancy from in vivo studies may be ascribed to the experimental condition, which is strictly controlled in a closed system. In a word, there is the possibility that the influence of other unidentified factors, which may relate to the redox balance on hypoxia-induced EPO production in vivo, is underestimated in in vitro research. Therefore, the possibility remains that hypoxia-induced EPO generation in vivo could be strongly affected by factors other than GSH.
It should be noted that our findings cannot exclude the possibility that other kinds of ROS may play a critical role in EPO production during hypoxic exposure. Regarding current "simulated altitude training," acute hypoxic exposure is needed immediately after exercise training, which may be accompanied by a massive amount of ROS generation. Our preliminary human study showing the inhibitory effect of prior severe exercise on subsequent hypoxia-induced formation of EPO and reticulocyte (unpublished observation) is in line with the speculation that some forms of ROS essentially contribute to hypoxia-induced EPO production through the regulation of HIF-1a (Gonzalez et al., 2002) . Yang et al. (2003) suggest that superoxide anion (O 2 Ϫ ) is closely involved in the activation of HIF-1a. They indicate that intracellular O 2 Ϫ production depresses HIF-1a increase in response to hypoxia, regardless of the resource of O 2 Ϫ . Moreover, the degradation of HIF-1a by O 2 Ϫ seems to occur independently of H 2 O 2 and OH · radicals in cells (Zou and Cowley, 2003) . To clarify these points, further investigation is required.
In conclusion, this is the first study to investigate the effect of renal GSH depletion on acute hypoxia-induced EPO production in intact animals. Our data reveal that the increase in serum EPO concentration by hypoxic exposure is not affected by the treatment of BSO. Hence, this study does not support the hypothesis that hypoxia-induced EPO secretion is primarily controlled by cellular redox changes in vivo.
